Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosimetry Study of Radioiodine Uptake with Thyrogen vs Withdrawal in Thyroid Cancer
NCT00001730Phase 4Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Dec 1997
- Modality
- Biologic, rProtein (Recombinant Protein), Hormone
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of thyrotropin alfa in thyroid cancer (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Ratio of administered activity of radioiodine (131I) to deliver a targeted dose of 30,000 rad. Started Dec 1997; status: completed.
02
Drugs
thyrotropin alfa
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT00001730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001730.